Johnson Controls Stock Hits New 52-Week High (JCI)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Johnson Controls (NYSE: JCI) hit a new 52-week high Thursday as it is currently trading at $35.29, above its previous 52-week high of $35.17 with 1.3 million shares traded as of 11:01 a.m. ET. Average volume has been 5.1 million shares over the past 30 days.

Johnson Controls has a market cap of $22.92 billion and is part of the consumer goods sector and automotive industry. Shares are up 11.6% year to date as of the close of trading on Wednesday.

Johnson Controls, Inc. engages in building efficiency, automotive experience, and power solutions businesses worldwide. The company has a P/E ratio of 25, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Johnson Controls as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. You can view the full Johnson Controls Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.

null

More from Markets

Stocks Tumble, Dow Futures Plunge as Growth Risks Catch Up to Global Markets

Stocks Tumble, Dow Futures Plunge as Growth Risks Catch Up to Global Markets

Market of the Week: E-mini S&P 500

Market of the Week: E-mini S&P 500

Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy

Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy

Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

Goldman Women Find Bias in Pay as Corporate Old-Boy Clubs Endure

Goldman Women Find Bias in Pay as Corporate Old-Boy Clubs Endure